Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.58 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398985 | 1.00 | HSD11B1 (0.58) | HSD11B1TNFRSF1AMAOBMAOACTSL | |
| SCHEMBL4900457 | 0.85 | HSD11B1 (0.62) | HSD11B1TNFRSF1AMAOBMAOAPOLB | |
| SCHEMBL9302644 | 0.84 | TRPM8 (0.58) | MAOBMAOAPOLBKMT2AAPP | |
| SCHEMBL10569133 | 0.84 | HSD11B1 (0.60) | HSD11B1TNFRSF1AMAOBMAOAMEN1 | |
| SCHEMBL9302651 | 0.84 | TRPM8 (0.58) | MAOBMAOAPOLBKMT2AAPP | |
| SCHEMBL6254356 | 0.82 | F3 (0.68) | MAOBMAOALMNAMAPT | |
| SCHEMBL2830756 | 0.82 | MAPT (0.54) | MAOBMAOAPOLBMEN1KMT2A | |
| SCHEMBL5677325 | 0.82 | RAB9A (0.58) | MAOBMAOAMEN1KMT2ALMNA | |
| SCHEMBL5677328 | 0.82 | RAB9A (0.58) | MAOBMAOAMEN1KMT2ALMNA | |
| SCHEMBL2830755 | 0.82 | MAPT (0.54) | MAOBMAOAPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024048438-A1 | DIASTEREOMER PREPARATION METHOD, AND SOLID-PHASE PHOTOSENSITIZER | 学校法人東京理科大学 | 2024-03-07 | — | — | WO | disclosed |
| EP-2825538-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | BRISTOL MYERS SQUIBB CO (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9108905-B2 | TRPA1 antagonists | ABBVIE INC. (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2825538-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | Bristol-Myers Squibb Company (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8765767-B2 | Positive allosteric modulators of mGluR2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2013138687-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20130245042-A1 | Positive Allosteric Modulators of MGLUR2 | BRISTOL-MYERS SQUIBB COMPANY | 2013-09-19 | — | — | US | disclosed |
| EP-2249820-A1 | TRPA1 ANTAGONISTS | Abbott Laboratories (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009089082-A1 | TRPA1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176883-A1 | TRPA1 Antagonists | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| US-7144881-B2 | Arylcyclopropylcarboxylic amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1565190-A4 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL MYERS SQUIBB CO (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-1565190-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004047738-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176883-A1 | TRPA1 Antagonists | TRPA1, TRPV1, TRPV3 | HSD11B1 3384/4885TNFRSF1A 1454/4885MAOB 1484/4885 |
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | KCNQ2, KCNQ5, KCNJ2 | HSD11B1 3320/4885TNFRSF1A 3103/4885MAOB 611/4885 |
| US-20130245042-A1 | Positive Allosteric Modulators of MGLUR2 | GRM2, GRM1, GRIN2C | HSD11B1 3402/4885TNFRSF1A 3540/4885MAOB 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.